Development of novel nucleoside analogues for use against drug resistant strains of HIV-1

Drug Discovery Today

Volumn 5, Issue 10, 2000, Pages 465-476

  Rando, Robert F ^a   Nguyen Ba, Nghe ^b  

^a PTC THERAPEUTICS   (United States)

^b BioChem Pharma   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; NUCLEOSIDE ANALOG; PHOSPHAZID; PRODRUG; TENOFOVIR; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; CROSS RESISTANCE; DRUG DEVELOPMENT; DRUG RESISTANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MUTATION; NONHUMAN; REVIEW;

EID: 0034307881     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6446(00)01558-0     Document Type: Review

References (66)

1. Levantis P.et al. Molecular and biological aspects of AZT resistant viruses derived from HIV-1 infected individuals. Antivral Chem. Chemother. 4:1993;131-138.
2. Riddler S.A.et al. Antiretroviral activity of stavudine (2′, 3′-didehydro-3′-deoxythymidine, d4T). Antiviral Res. 27:1995;189-203.
3. Perry C.M., Balfour J.A. Didanosine: an update on its antiviral activity, pharmacokinetic properties and therapeutic efficacy in the management of HIV disease. Drugs. 52:1996;928-962.
4. Skowron G. ddC (zalcitabine). Adv. Exp. Med. Biol. 394:1996;257-269.
5. Cameron J.M.et al. Lamivudine. Drugs Future. 1:1993;319-323.
6. Daluge S.M.et al. 1592U89, a novel carbocyclic nucleoside analog with potent, selective anti-human immunodeficiency virus activity. Antimicrob. Agents Chemother. 41:1997;1082-1093.
7. Schmit J-C., Weber B. Recent advances in antiretroviral therapy and HIV infection monitoring. Intervirology. 40:1998;304-321.
8. Furman P.A.et al. Phosphorylation of 3′-azido-3′-deoxythymidine and selective interaction of the 5′-triphosphate with human immunodeficiency virus reverse transcriptase. Proc. Natl. Acad. Sci. U. S. A. 83:1986;8333-8337.
9. Hart G.J.et al. Effect of (-)2′-deoxy-3′-thiacytidine (3TC) 5′-triphosphate on human immunodeficiency virus reverse transcriptase and mammalian DNA polymerase α, β and γ Antimicrob. Agents Chemother. 36:1992;1688-1694.
10. Mitsuya H., Broder S. Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotrophic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) by 2′,3′-dideoxynucleosides. Proc. Natl. Acad. Sci. U. S. A. 83:1986;1911-1915.
11. St Clair M.et al. 3′-azido-3′-deoxythymidine triphosphate as an inhibitor and substrate of purified human immunodeficiency virus reverse transcriptase. Antimicrob. Agents Chemother. 3:1987;1972-1977.
12. Yarchoan R.et al. Clinical pharmacology of 3′-azido-2′,3′-dideoxythymidine (zidovudine) and related dideoxynucleosides. New Engl. J. Med. 321:1989;726-738.
13. Hao Z.et al. Factors determining the activity of 2′,3′-dideoxynucleosides in suppressing human immunodeficiency virus in vitro. Mol. Pharmacol. 34:1988;431-435.
14. Wainberg M.A., Friedland G. Public health implications of antiretroviral therapy and HIV drug resistance. J. Am. Med. Assoc. 279:1998;1977-1983.
15. Ho D.et al. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Science. 273:1995;123-126.
16. Wei X.et al. Viral dynamics in human immunodeficiency virus type 1 infection. Science. 273:1995;117-122.
17. Coffin J.M. HIV population dynamics in vivo: Implications for genetic variation, pathogenesis, and therapy. Science. 267:1995;483-489.
18. + T cell homeostasis and function in advanced HIV disease. Science. 277:1997;112-116.
19. Perelson A.S.et al. Decay characteristics of HIV-1 infected compartments during combination therapy. Nature. 387:1997;188-191.
20. Carpenter C.C.J.et al. Antiretroviral therapy for HIV infection in 1997. Update recommendations of the international AIDS society-USA panel. J. Am. Med. Assoc. 277:1997;1962-1969.
21. Shirasaka T.et al. Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides. Proc. Natl. Acad. Sci. U. S. A. 92:1995;2398-2402.
22. Gu Z.et al. Mutated K65R recombinant HIV-1 reverse transcriptase shows diminished chain termination in the presence of 2′,3′-dideoxycytidine-5′-triphosphate and other drugs. Proc. Natl. Acad. Sci. U. S. A. 92:1995;2760-2764.
23. Larder B.A., Kemp S.D. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science. 246:1989;1155-1158.
24. Schuurman R.et al. Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant populations in persons treated with lamivudine (3TC). J. Infect. Dis. 171:1995;1411-1419.
25. St Clair M.H.et al. Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. Science. 253:1991;1557-1559.
26. Boucher C.A.B.et al. High-level resistance to (-) enantiomeric 2′-deoxy-3′-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase. Antimicrob. Agents Chemother. 37:1993;2231-2234.
27. Boucher C.A.B.et al. Ordered appearance of zidovudine resistant mutations during treatment of 18 human immunodeficiency virus-positive subjects. J. Infect. Dis. 165:1992;105-110.
28. Boulerice F.et al. High frequency of isolation of defective human immunodeficiency virus type 1 and heterogeneity of viral gene expression in clones of infected U-937 cells. J. Virol. 64:1990;1745-1755.
29. Harrigan P.R.et al. Significance of amino acid variation at human immunodeficiency virus type 1 reverse transcriptase residue 210 for zidovudine susceptibility. J. Virol. 70:1996;5930-5934.
30. Kellaam P.et al. Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high level resistance to zidovudine. Proc. Natl. Acad. Sci. U. S. A. 89:1992;1934-1938.
31. Salomon H.et al. Prevalence of HIV-1 resistant to antiretroviral drugs in 81 individuals newly infected by sexual contact or injecting drug use. AIDS. 14:2000;F17-F23.
32. Paff M.T.et al. Intracellular metabolism of (-)- and (+)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine in HepG2 derivative 2.2.15 (subclone P5A) cells. Antimicrob. Agents Chemother. 38:1994;1230-1238.
33. Schinazi R.F.et al. Selective inhibition of human immunodeficiency virus by racemates and enatiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine. Antimicrob. Agents Chemother. 36:1992;2423-2431.
34. Soudeyns H.et al. Anti-human immunodeficiency virus type 1 activity and in vitro toxicity of 2′-deoxy-3′-thiacytidine (BCH-189), a novel heterocyclic nucleoside analog. Antimicrob. Agents Chemother. 35:1991;1386-1390.
35. Mathez D.et al. Infectious amplification of wild-type human immunodeficiency virus from patients' lymphocytes and modulation by reverse transcriptase inhibitors in vitro. Antimicrobial. Agents Chemother. 37:1993;2206-2211.
36. Bridges E.G.et al. Favorable interactions of β-L(-) nucleoside analogues with clinically approved anti-HIV nucleoside analogues for the treatment of human immunodeficiency virus. Biochem. Pharmacol. 51:1996;731-736.
37. Gu Z.et al. Mechanism of action and in vitro activity of 1′,3′-dioxolanylpurine nucleoside analogues against sensitive and drug-resistant human immunodeficiency virus type 1 variants. Antimicrobial. Agents Chemother. 43:1999;2376-2382.
38. Kim K.O.et al. 1,3-dioxolanylpurine nucleosides (2R,4R) and (2R,4S) with selective anti-HIV-1 activity in human lymphocytes. J. Med. Chem. 36:1993;30-37.
39. Rajagopalan P.et al. Pharmacokinetics of (-)-β-D-2,6-diaminopurine dioxolane and its metabolite guanosine in rhesus monkeys. Pharm. Res. 11(Suppl.):1994;381-386.
40. Rajagopalan P.et al. Pharmacokinetics of (-)-β-D-2,6-diaminopurine dioxolane and its metabolite, dioxolane guanosine, in woodchucks (marmota monax). Antiviral Chem. Chemother. 7:1996;65-70.
41. De Clercq E.et al. (S)-9-(2,3-dihydroxypropyl)adenine: an aliphatic nucleoside analog with broad-spectrum antiviral activity. Science. 200:1978;563-565.
42. De Clercq E. In search of a selective antiviral chemotherapy. Clin. Microbiol. Rev. 10:1997;674-693.
43. Tsai C.C.et al. Effects of (R)-9-(2-phosphonylmethoxypropyl) adenine monotherapy on chronic SIV infection in macaques. AIDS Res. Hum. Retroviruses. 13:1997;707-712.
44. Tsai C.C.et al. Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl)adenine. Science. 270:1995;1197-1199.
45. Srinivas R.V., Fridland A. Antiviral activities of 9-R-2-phosphonomethoxypropyl adenine (PMPA) and bis(isopropyloxy-methylcarbonyl)PMPA against various drug-resistant human immunodeficiency virus strains. Antimicrob. Agents Chemother. 42:1998;1484-1487.
46. Deeks S.G.et al. Safety, pharmacokinetics, and antiretroviral activity of intravenous 9-[2-(R)-(phosphonomethoxy)propyl]adenine, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults. Antimicrob. Agents Chemother. 42:1998;2380-2384.
47. Tarussova N.B.et al. Inhibition of human immunodeficiency virus (HIV) production by 5′-hydrogenphosphonates of 3′-azido-2′,3′-dideoxynucleosides. Nucleosides Nucleotides. 10:1991;351-354.
48. Machado J.et al. Antiviral activity and resistance profile of phosphazid - a novel prodrug of AZT. Nucleosides Nucleotides. 18:1999;901-906.
49. Tsoukas C.et al. A phase I study of PZT (3′-azido-2′,3′dideoxythymidine-5′H-phosphonate) in patients with HIV infection. Antiviral Ther. 3:1998;83-84.
50. De Muys J-M.et al. Anti-human immunodeficiency virus type 1 activity, intracellular metabolism, and pharmacokinetic evaluation of 2′-deoxy-3′-oxa-4′-thiocytidine. Antimicrob. Agents Chemother. 43:1999;1834-1844.
51. Stoddart C.A.et al. Antiviral activity of 2′-deoxy-3′-oxa-4′-thiocytidine (BCH-10652) against lamivudine-resistant human immunodeficiency virus type 1 in SCID-hu Thy/Liv mice. Antimicrob. Agents Chemother. 44:2000;783-786.
52. Richard N.et al. Selection and characterization of HIV-1 variants resistant to the (+) and (-) enantiomers of 2′-deoxy-3′-oxa-4′-thiocytidine (dOTC). Antiviral Ther. 4:1999;171-177.
53. Marquez V.E.et al. 2′,3′-dideoxy-2′-fluoro-ara-A. An acid soluble purine nucleoside active against human immunodeficiency virus (HIV). Biochem. Pharmacol. 36:1987;2719-2722.
54. Driscol J.S.et al. 2′-Fluoro-2′,3′-dideoxyarabinosyladenine (F-ddA): activity against drug-resistant human immunodeficiency virus strains and clades A-E. Antiviral Chem. Chemother. 8:1997;107-111.
55. Tanaka M.et al. In vitro induction of human immunodeficiency virus type 1 variants resistant to 2′-β-fluoro-2′,3′-dideoxyadenosine. Antimicrob. Agents Chemother. 41:1997;1313-1318.
56. Buckheit R.W. Jr. et al. Anti-human immunodeficiency virus type 1 (HIV-1) activity of 2′-fluoro-2′,3′-dideoxyarabinosyladenine (FddA) used in combination with other mechanistically diverse inhibitors of HIV-1 replication. Antiviral Chem. Chemother. 10:1999;115-119.
57. Gu Z.et al. Identification of a mutation at codon 65 in the IKKK motif of reverse transcriptase that encode human immunodeficiency virus resistance to 2′,3′-dideoxycytidine and 2′,3′-dideoxy-3′-thiacytidine. Antimicrob. Agents Chemother. 38:1994;275-281.
58. Barditch-Crovo P.et al. Anti-human immunodeficiency virus (HIV) activity, safety, and pharmacokinetics of adefovir dipivoxil (9-[2-(bis-pivaloylomethyl)-phosphonomethoxymethyl]adenine) in HIV-infected patients. J. Infect. Dis. 176:1997;406-413.
59. Hitchcock M.J.M.et al. The cyclic congener of cidofovir has reduced nephrotoxicity in three species. Antiviral Res. 26:1995;A358.
60. Tan X.et al. Development and optimization of anti-HIV nucleoside analogs and prodrugs: A review of their cellular pharmacology, structure-activity relationships and pharmacokinetics. Adv. Drug Deliv. Rev. 39:1999;117-151.
61. Riddler S.A.et al. Safety and pharmacokinetics of 5-chloro-2′,3′-dideoxy-3′-fluorouridine (935U83) following oral administration of escalating single doses in human immunodeficiency virus-infected adults. Antimicrob. Agents Chemother. 40:1996;2842-2847.
62. Maga G.et al. Molecular basis for the enantioselectivity of HIV-1 reverse transcriptase: role of the 3′-hydroxyl group of the L-(β)-ribose in chiral discrimination between D- and L-enantiomers of deoxy- and dideoxy-nucleoside triphophate analogs. Nucleic Acids Res. 27:1999;972-978.
63. Dutschman G.E.et al. Metabolism of 2′,3′-dideoxy-2′3′-didehydro-β-L(-)-5-fluorocytidine and its activity in combination with clinically approved anti-human immunodeficiency virus β-D(+) nucleoside analogs in vitro. Antimicrob. Agents Chemother. 42:1998;1799-1804.
64. Lee K.et al. Synthesis and anti-HIV and anti-HBV activities of 2′ -fluoro-2′,3′-unsaturated L-nucleosides. J. Med. Chem. 42:1999;1320-1328.
65. Mansour T.S.et al. Anti-HIV and anti-HBV activities of L-2′,3′-dideoxynucleoside analogues: ddC, 5FddC, 5-Aza ddC and ddG. Med. Chem. Res. 5:1995;417-425.
66. Schinazi R.F.et al. Mutations in retroviral genes associated with drug resistance. Int. Antiviral News. 5:1997;129.